Skip to content
DataLookout
Menu

NCT07606937

A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.

StatusActive, Not Recruiting
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 31, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
  2. Notable Start date: May 1, 2026 to Jun 12, 2026v2 Show 4 more changesShow less
    • Eligibility criteria shortened, about 5 words
    • Secondary endpoints: details revised at 3 of 4 entries
    • Study description expanded, about 3 words
    • Study title shortened, about 2 words
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Objective response rate (ORR)
Timeframe: Up to 24 months

Secondary (4)

Complete response rate (CRR)
Duriation of response (DOR)
Progression-frees survival (PFS)
Overall survival(OS)

Arms and interventions

FKC876 injectionExperimental

Drugs: FKC876 injection

Sites

6 sites in 1 country